Home > Newsletters > Clinical Trials Advisor > Good Communication Can Minimize Disruptions During IRB Transfers
Clinical Trials Advisor
June 21, 2012 | Vol. 17 No. 13
Good Communication Can Minimize Disruptions During IRB Transfers
To smoothly transition clinical investigation oversight from one IRB to another, new and old IRBs, clinical investigators, sponsors and CROs should work closely to minimize disruptions to the ongoing trial and ensure subjects are constantly protected, according to a new draft guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.